<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37715729</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1843</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Respirology (Carlton, Vic.)</Title><ISOAbbreviation>Respirology</ISOAbbreviation></Journal><ArticleTitle>Treatable traits for long COVID.</ArticleTitle><Pagination><StartPage>1005</StartPage><EndPage>1022</EndPage><MedlinePgn>1005-1022</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/resp.14596</ELocationID><Abstract><AbstractText>Long COVID, or post-acute COVID-19 sequelae, is experienced by an estimated one in eight adults following acute COVID-19. Long COVID is a new and complex chronic health condition that typically includes multiple symptoms that cross organ systems and fluctuate over time; a one-size-fits-all approach is, therefore, not likely to be appropriate nor relevant for long COVID treatment. 'Treatable Traits' is a personalized medicine approach, purpose-built to address the complexity and heterogeneity of complex chronic conditions. This comprehensive review aimed to understand how a treatable traits approach could be applied to long COVID, by first identifying the most prevalent long COVID treatable traits and then the available evidence for strategies to target these traits. An umbrella review of 22 systematic reviews identified 34 symptoms and complications common with long COVID, grouped into eight long COVID treatable trait clusters: neurological, chest, psychological, pain, fatigue, sleep impairment, functional impairment and other. A systematic review of randomized control trials identified 18 studies that explored different intervention approaches for long COVID prevention (k&#x2009;=&#x2009;4) or management (k&#x2009;=&#x2009;14). While a single study reported metformin as effective for long COVID prevention, the findings need to be replicated and consensus is required around how to define long COVID as a clinical trial endpoint. For long COVID management, current evidence supports exercise training or respiratory muscle training for long COVID treatable traits in the chest and functional limitation clusters. While there are studies exploring interventions targeting other long COVID treatable traits, further high-quality RCTs are needed, particularly targeting treatable traits in the clusters of fatigue, psychological, pain and sleep impairment.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Respirology published by John Wiley &amp; Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewthwaite</LastName><ForeName>Hayley</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5212-2937</Identifier><AffiliationInfo><Affiliation>Centre of Research Excellence Treatable Traits, College of Health, Medicine, and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asthma and Breathing Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Heart Lung Clinic, Department of Thoracic Medicine St Vincent's Hospital and Clinical School University of New South Wales, Darlinghurst, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brew</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Peter Duncan Neuroscience Research Unit, St. Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Immunology, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Notre Dame, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0001-5865-489X</Identifier><AffiliationInfo><Affiliation>Centre of Research Excellence Treatable Traits, College of Health, Medicine, and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Asthma and Breathing Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Respirology</MedlineTA><NlmUniqueID>9616368</NlmUniqueID><ISSNLinking>1323-7799</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">disease management</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">long haul COVID</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">precision medicine</Keyword><Keyword MajorTopicYN="N">treatable traits</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>16</Day><Hour>20</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37715729</ArticleId><ArticleId IdType="doi">10.1111/resp.14596</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Munblit D, O'Hara ME, Akrami A, Perego E, Olliaro P, Needham DM. Long COVID: aiming for a consensus. Lancet Respir Med. 2022;10:632-634.</Citation></Reference><Reference><Citation>Callard F, Perego E. How and why patients made long COVID. Soc Sci Med. 2021;268:113426.</Citation></Reference><Reference><Citation>Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110-118.</Citation></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F. For the gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603-605.</Citation></Reference><Reference><Citation>Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021;325:2015-2016.</Citation></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after COVID-19: qualitative study of 114 "long COVID" patients and draft quality principles for services. BMC Health Serv Res. 2020;20:1144.</Citation></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275-1287.</Citation></Reference><Reference><Citation>Darley DR, Dore GJ, Cysique L, Wilhelm KA, Andresen D, Tonga K, et al. Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Med J Aust. 2021;214:279-280.</Citation></Reference><Reference><Citation>de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-534.</Citation></Reference><Reference><Citation>World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. 2023. [accessed 2023 Jun 11]. Available from: https://covid19.who.int</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102-e107.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. 2021. [accessed 2023 Jun 11]. Available from: https://www.nice.org.uk/guidance/ng188</Citation></Reference><Reference><Citation>National Clinical Evidence Taskforce. Australian Guidelines for the Clinical Care of People with COVID-19. 2023. [accessed 2023 Jun 11]. Available from: https://app.magicapp.org/#/guideline/L4Q5An/section/jN222G</Citation></Reference><Reference><Citation>Centres for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers. 2022. [accessed 2023 Jun 11]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html#:~:text=CDC%20considers%20Post%2DCOVID%20Conditions,persistent%20illness%20becomes%20more%20likely</Citation></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934-1946.</Citation></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624.</Citation></Reference><Reference><Citation>Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of long COVID-19 caused by different SARS-CoV-2 strains: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:16010.</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263-2264.</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43-55.</Citation></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk factors associated with post&#x2212;COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183:566-580.</Citation></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat Med. 2021;27:1129-1130.</Citation></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022;400:452-461.</Citation></Reference><Reference><Citation>Brightling CE, Evans RA. Long COVID: which symptoms can be attributed to SARS-CoV-2 infection? Lancet. 2022;400:411-413.</Citation></Reference><Reference><Citation>Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604-1615.</Citation></Reference><Reference><Citation>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747-758.</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706-1714.</Citation></Reference><Reference><Citation>Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, et al. Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis. J Clin Med. 2022;11:1541.</Citation></Reference><Reference><Citation>Liu B, Jayasundara D, Pye V, Dobbins T, Dore GJ, Matthews G, et al. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. Lancet Reg Health West Pac. 2021;12:100193.</Citation></Reference><Reference><Citation>Pfaff ER, Madlock-Brown C, Baratta JM, Bhatia A, Davis H, Girvin A, et al. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21:58.</Citation></Reference><Reference><Citation>Steven P, Williams MA. Confronting our next National Health Disaster-long-haul covid. N Engl J Med. 2021;385:577-579.</Citation></Reference><Reference><Citation>Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410-419.</Citation></Reference><Reference><Citation>Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology. 2017;22:1262-1275.</Citation></Reference><Reference><Citation>Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J. Effectiveness of interventions targeting treatable traits for the management of obstructive airway diseases: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2022;10(9):2333-2345.e21.</Citation></Reference><Reference><Citation>McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2020;55:1901509.</Citation></Reference><Reference><Citation>McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68:691-694.</Citation></Reference><Reference><Citation>McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report. Eur Respir J. 2019;53:1802058.</Citation></Reference><Reference><Citation>George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7:34-51.</Citation></Reference><Reference><Citation>Faulkner G, Fagan MJ, Lee J. Umbrella reviews (systematic review of reviews). Int Rev Sport Exerc Psychol. 2022;15:73-90.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation></Reference><Reference><Citation>Pieper D, Antoine S-L, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67:368-375.</Citation></Reference><Reference><Citation>Pollock M, Fernandes RM, Newton AS, Scott SD, Hartling L. A decision tool to help researchers make decisions about including systematic reviews in overviews of reviews of healthcare interventions. Syst Rev. 2019;8:29.</Citation></Reference><Reference><Citation>Francesca Reyes D, Lisa AW, Angela MC, Curtis LC, Veronica JB, Alexandra MEZ, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review. medRxiv. 2021; 2021.06.03.21258317.</Citation></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021;92:55-70.</Citation></Reference><Reference><Citation>Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100899.</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6:e005427.</Citation></Reference><Reference><Citation>Alkodaymi MS, Omrani OA, Fawzy NA, Abou Shaar B, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:657-666.</Citation></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, Diella L, Fiore Bavaro D, Bonica R, et al. Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients. Intern Emerg Med. 2022;18:1-9.</Citation></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269.</Citation></Reference><Reference><Citation>Huang Q, Jia M, Sun Y, Jiang B, Cui D, Feng L, et al. One-year temporal changes in long COVID prevalence and characteristics: a systematic review and meta-analysis. Value Health. 2022;26:934-942.</Citation></Reference><Reference><Citation>Yang TQ, Yan MZP, Li XY, Lau EHY. Sequelae of COVID-19 among previously hospitalized patients up to 1 year after discharge: a systematic review and meta-analysis. Infection. 2022;50:1067-1109.</Citation></Reference><Reference><Citation>Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28:423-433.</Citation></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2022;4:fcab297.</Citation></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93-135.</Citation></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022;434:120162.</Citation></Reference><Reference><Citation>Zuin M, Rigatelli G, Bilato C, Porcari A, Merlo M, Roncon L, et al. One-year risk of myocarditis after COVID-19 infection: a systematic review and meta-analysis. Can J Cardiol. 2022;39:839-844.</Citation></Reference><Reference><Citation>Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: a systematic review and meta-analysis. Int J Cardiol. 2023;372:138-143.</Citation></Reference><Reference><Citation>Trott M, Driscoll R, Pardhan S. The prevalence of sensory changes in post-COVID syndrome: a systematic review and meta-analysis. Front Med. 2022;9:980253.</Citation></Reference><Reference><Citation>Lee JH, Yim JJ, Park J. Pulmonary function and chest computed tomography abnormalities 6-12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res. 2022;23:233.</Citation></Reference><Reference><Citation>Zheng B, Daines L, Han Q, Hurst JR, Pfeffer P, Shankar-Hari M, et al. Prevalence, risk factors and treatments for post-COVID-19 breathlessness: a systematic review and meta-analysis. Eur Resp Rev. 2022;31:220071.</Citation></Reference><Reference><Citation>Fernandez-de-las-Penas C, Navarro-Santana M, Plaza-Manzano G, Palacios-Cena D, Arendt-Nielsen L. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Pain. 2022;163:1220-1231.</Citation></Reference><Reference><Citation>Fernandez-de-las-Penas C, Navarro-Santana M, Gomez-Mayordomo V, Cuadrado ML, Garcia-Azorin D, Arendt-Nielsen L, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 2021;28:3820-3825.</Citation></Reference><Reference><Citation>Choudhury A, Tariq R, Jena A, Vesely EK, Singh S, Khanna S, et al. Gastrointestinal manifestations of long COVID: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2022;15:17562848221118403.</Citation></Reference><Reference><Citation>Jimeno-Almazan A, Franco-Lopez F, Buendia-Romero A, Martinez-Cava A, Sanchez-Agar JA, Martinez BJSA, et al. Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial. Scand J Med Sci Sports. 2022;32:1791-1801.</Citation></Reference><Reference><Citation>Jimeno-Almazan A, Buendia-Romero A, Martinez-Cava A, Franco-Lopez F, Sanchez-Alcaraz BJ, Courel-Ibanez J, et al. Effects of a concurrent training, respiratory muscle exercise, and self-management recommendations on recovery from post-COVID-19 conditions: the RECOVE trial. J Appl Physiol. 2023;134:95-104.</Citation></Reference><Reference><Citation>Catalogna M, Sasson E, Hadanny A, Parag Y, Zilberman-Itskovich S, Efrati S. Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: a randomized, sham-controlled trial. Neuroimage Clin. 2022;36:103218.</Citation></Reference><Reference><Citation>Zilberman-Itskovich S, Catalogna M, Sasson E, Elman-Shina K, Hadanny A, Lang E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12:11252.</Citation></Reference><Reference><Citation>Barros C, Freire RS, Frota E, Rezende Santos AG, Farias MEL, Rodrigues MGA, et al. Short-course of methylprednisolone improves respiratory functional parameters after 120&#x2009;days in hospitalized COVID-19 patients (Metcovid Trial): a randomized clinical trial. Front Med. 2021;8:758405.</Citation></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;S1473-3099(23)00299-2. doi:10.1016/S1473-3099(23)00299-2.</Citation></Reference><Reference><Citation>Korper S, Gruner B, Zickler D, Wiesmann T, Wuchter P, Blasczyk R, et al. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J Clin Invest. 2022;132:e163657.</Citation></Reference><Reference><Citation>Nevalainen OPO, Horstia S, Laakkonen S, Rutanen J, Mustonen JMJ, Kalliala IEJ, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022;13:6152.</Citation></Reference><Reference><Citation>Dal Negro RW, Turco P, Povero M. Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia-a pivotal double-blind, cross-over controlled study. Multidiscip Respir Med. 2022;17:886.</Citation></Reference><Reference><Citation>Del Corral T, Fabero-Garrido R, Plaza-Manzano G, Fernandez-de-Las-Penas C, Navarro-Santana M, Lopez-de-Uralde-Villanueva I. Home-based respiratory muscle training on quality of life and exercise tolerance in long-term post-COVID-19: randomized controlled trial. Ann Phys Rehabil Med. 2023;66:101709.</Citation></Reference><Reference><Citation>De Luca P, Camaioni A, Marra P, Salzano G, Carriere G, Ricciardi L, et al. Effect of ultra-micronized palmitoylethanolamide and luteolin on olfaction and memory in patients with long COVID: results of a longitudinal study. Cell. 2022;11:2552.</Citation></Reference><Reference><Citation>Hawkins J, Hires C, Keenan L, Dunne E. Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: a randomized, double-blinded, placebo controlled clinical trial. Complement Ther Med. 2022;67:102823.</Citation></Reference><Reference><Citation>McNarry MA, Berg RMG, Shelley J, Hudson J, Saynor ZL, Duckers J, et al. Inspiratory muscle training enhances recovery post-COVID-19: a randomised controlled trial. Eur Respir J. 2022;60:2103101.</Citation></Reference><Reference><Citation>Palau P, Dom&#xed;nguez E, Gonzalez C, Bond&#xed;a E, Albiach C, Sastre C, et al. Effect of a home-based inspiratory muscle training programme on functional capacity in postdischarged patients with long COVID: the InsCOVID trial. BMJ Open Respir Res. 2022;9:e001255.</Citation></Reference><Reference><Citation>Romanet C, Wormser J, Fels A, Lucas P, Prudat C, Sacco E, et al. Effectiveness of endurance training rehabilitation after hospitalisation in intensive care for COVID-19 related acute respiratory distress syndrome on dyspnoea (RECOVER): a randomised controlled, open-label multicentre trial. medRxiv. 2022; 30.</Citation></Reference><Reference><Citation>Santana K, Fran&#xe7;a E, Sato J, Silva A, Queiroz M, de Farias J, et al. Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC). Brain Stimul. 2023;16:100-107.</Citation></Reference><Reference><Citation>Tosato M, Calvani R, Picca A, Ciciarello F, Galluzzo V, Coelho-Junior HJ, et al. Effects of l-arginine plus vitamin C supplementation on physical performance, endothelial function, and persistent fatigue in adults with long COVID: a single-blind randomized controlled trial. Nutrients. 2022;14:4984.</Citation></Reference><Reference><Citation>Yan CH, Jang SS, Lin HFC, Ma Y, Khanwalkar AR, Thai A, et al. Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial. Int Forum Allergy Rhinol. 2023;13:989-997.</Citation></Reference><Reference><Citation>Dwolatzky T, Whitehead V, Doniger GM, Simon ES, Schweiger A, Jaffe D, et al. Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatr. 2003;3:4.</Citation></Reference><Reference><Citation>Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22:39-52.</Citation></Reference><Reference><Citation>Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-e64.</Citation></Reference><Reference><Citation>Banzett RB, O'Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, Meek PM, et al. Multidimensional dyspnea profile: an instrument for clinical and laboratory research. Eur Respir J. 2015;45:1681-1691.</Citation></Reference><Reference><Citation>Stein KD, Martin SC, Hann DM, Jacobsen PB. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract. 1998;6:143-152.</Citation></Reference><Reference><Citation>Herrera JE, Niehaus WN, Whiteson J, Azola A, Baratta JM, Fleming TK, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM&amp;R. 2021;13:1027-1043.</Citation></Reference><Reference><Citation>Munblit D, Nicholson T, Akrami A, Apfelbacher C, Chen J, De Groote W, et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10:715-724.</Citation></Reference><Reference><Citation>Australian Institute of Health and Wellness. Chronic Conditions and Multimorbidity. 2022. [accessed 2023 Jun 11]. Available from: https://www.aihw.gov.au/reports/australias-health/chronic-conditions-and-multimorbidity</Citation></Reference><Reference><Citation>Roberts KC, Rao DP, Bennett TL, Loukine L, Jayaraman GC. Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada. Health Promot Chronic Dis Prev Can. 2015;35:87-94.</Citation></Reference><Reference><Citation>Wiernsperger N, Al-Salameh A, Cariou B, Lalau JD. Protection by metformin against severe Covid-19: an in-depth mechanistic analysis. Diabetes Metab. 2022;48:101359.</Citation></Reference><Reference><Citation>Bailey CJ, Gwilt M. Diabetes, metformin and the clinical course of Covid-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin. Front Pharmacol. 2022;13:784459.</Citation></Reference><Reference><Citation>McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2:CD003793.</Citation></Reference><Reference><Citation>Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021;2:CD006322.</Citation></Reference><Reference><Citation>Osadnik CR, Gleeson C, McDonald VM, Holland AE. Pulmonary rehabilitation versus usual care for adults with asthma. Cochrane Database Syst Rev. 2022;8:CD013485.</Citation></Reference><Reference><Citation>Ammous O, Feki W, Lotfi T, Khamis AM, Gosselink R, Rebai A, et al. Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2023;1:CD013778.</Citation></Reference><Reference><Citation>Woollett P, Scales C, Howden E, Nutler N, Fon A, Lewthwaite H. Exercise and Sports Science Australia COVID-19 Exercise Guidelines. 2022. [accessed 2023 Jun 11]. Available from: https://www.essa.org.au/Public/Research/Covid-19_Exercise_Guidelines/Public/COVID_19/Covid-19_Exercise_Guidelines.aspx?hkey=1c00a948-4638-4212-a81b-633c9b4939c1</Citation></Reference><Reference><Citation>World Health Organisation. Clinical Management of COVID-19: Living Guideline. 2023. [accessed 2023 Jun 11]. Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCOV-clinical-2023.1</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management. 2021. [accessed 2023 Jun 11]. Available from: https://www.nice.org.uk/guidance/ng206</Citation></Reference><Reference><Citation>Woods AJ, Antal A, Bikson M, Boggio PS, Brunoni AR, Celnik P, et al. A technical guide to tDCS, and related non-invasive brain stimulation tools. Clin Neurophysiol. 2016;127:1031-1048.</Citation></Reference><Reference><Citation>Ferrucci R, Vergari M, Cogiamanian F, Bocci T, Ciocca M, Tomasini E, et al. Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis. NeuroRehabilitation. 2014;34:121-127.</Citation></Reference><Reference><Citation>Andrade SM, de Araujo C, Silvestre M, de Franca EET, Bezerra Sales Queiroz MH, de Jesus Santana K, et al. Efficacy and safety of HD-tDCS and respiratory rehabilitation for critically ill patients with COVID-19 The HD-RECOVERY randomized clinical trial. Brain Stimul. 2022;15:780-788.</Citation></Reference><Reference><Citation>Hsu WY, Cheng CH, Zanto TP, Gazzaley A, Bove RM. Effects of transcranial direct current stimulation on cognition, mood, pain, and fatigue in multiple sclerosis: a systematic review and meta-analysis. Front Neurol. 2021;12:626113.</Citation></Reference><Reference><Citation>De Doncker W, Ondobaka S, Kuppuswamy A. Effect of transcranial direct current stimulation on post-stroke fatigue. J Neurol. 2021;268:2831-2842.</Citation></Reference><Reference><Citation>Forogh B, Rafiei M, Arbabi A, Motamed MR, Madani SP, Sajadi S. Repeated sessions of transcranial direct current stimulation evaluation on fatigue and daytime sleepiness in Parkinson's disease. Neurol Sci. 2017;38:249-254.</Citation></Reference><Reference><Citation>Severin R, Franz CK, Farr E, Meirelles C, Arena R, Phillips SA, et al. The effects of COVID-19 on respiratory muscle performance: making the case for respiratory muscle testing and training. Eur Respir Rev. 2022;31:220006.</Citation></Reference><Reference><Citation>Agust&#xed; A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017;50:1-13.</Citation></Reference><Reference><Citation>Hiles SA, Gibson PG, Agusti A, McDonald V. Treatable traits that predict health status and treatment response in airway disease. J Allergy Clin Immunol Pract. 2021;9:1255-1264.e2.</Citation></Reference><Reference><Citation>Agusti A, Barnes N, Cruz AA, Gibson PG, Heaney LG, Inoue H, et al. Moving towards a treatable traits model of care for the management of obstructive airways diseases. Respir Med. 2021;187:106572.</Citation></Reference><Reference><Citation>Agusti A, Gibson PG, McDonald VM. Treatable traits in airway disease: from theory to practice. J Allergy Clin Immunol Pract. 2023;11:713-723.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>